Profile data is unavailable for this security.
About the company
PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.
- Revenue in SEK (TTM)51.91m
- Net income in SEK-43.42m
- Incorporated2003
- Employees37.00
- LocationPMD Device Solutions ABFogdevreten 2 BSOLNA 171 65SwedenSWE
- Phone+46 850884744
- Websitehttps://investors.pmd-solutions.com/
Mergers & acquisitions
| Acquired company | PMDS:STO since announced | Transaction value |
|---|---|---|
| Coala-Life Inc | -84.15% | -- |
| PMD Device Solutions AB | -78.02% | 13.23m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Codelab Capital AS | -98.44bn | -98.44bn | 23.08m | 29.00 | -- | 0.1484 | -- | -- | -- | -- | -- | 0.4624 | -- | -- | -- | -- | -- | -6.63 | -- | -7.43 | -- | 83.80 | -- | -39.82 | -- | -- | 0.00 | -- | -69.66 | -3.83 | 119.43 | -- | -12.19 | -- |
| Bio Vitos Pharma AB | 1.11m | -14.84m | 26.40m | 1.00 | -- | 0.7407 | -- | 23.81 | -1.50 | -1.50 | 0.0597 | 0.9046 | 0.0457 | 0.092 | 3.02 | 1,108,910.00 | -61.08 | -31.11 | -62.90 | -32.92 | 90.59 | -- | -1,338.03 | -1,026.76 | 5.84 | -- | 0.00 | -- | 126.97 | -- | 13.64 | -- | -- | -- |
| Inhalation Sciences Sweden AB | 15.48m | -3.93m | 27.45m | 8.00 | -- | 2.44 | -- | 1.77 | -0.2796 | -0.2796 | 1.09 | 0.7409 | 0.8096 | 0.6328 | 4.37 | 1,935,000.00 | -20.53 | -27.93 | -29.23 | -43.82 | 86.29 | 71.13 | -25.36 | -48.02 | 2.81 | -6.49 | 0.0639 | -- | 43.55 | 26.33 | 60.87 | -- | -- | -- |
| BBS-Bioactive Bone Substitutes Oyj | 0.00 | -41.16m | 28.62m | -- | -- | 0.528 | -- | -- | -0.2069 | -0.2069 | 0.00 | 0.1765 | 0.00 | -- | -- | -- | -35.38 | -25.12 | -45.41 | -28.54 | -- | -- | -- | -- | -- | -27.51 | 0.5953 | -- | -- | -- | -12.64 | -- | -- | -- |
| ProstaLund AB | 17.57m | -21.64m | 31.37m | 6.00 | -- | 0.4508 | -- | 1.79 | -0.2752 | -0.2752 | 0.2226 | 0.5656 | 0.2627 | 0.3308 | 12.78 | -- | -32.35 | -29.14 | -39.54 | -35.01 | 72.73 | 75.26 | -123.16 | -68.94 | 0.7618 | -155.80 | 0.1065 | -- | 27.54 | 10.36 | -53.27 | -- | 20.35 | -- |
| Scandinavian Real Heart AB | 0.00 | -75.02m | 37.64m | 12.00 | -- | 0.4113 | -- | -- | -0.5182 | -0.5182 | 0.00 | 0.4425 | 0.00 | -- | -- | 0.00 | -73.46 | -24.27 | -87.03 | -26.81 | -- | 832.41 | -- | -6,070.11 | -- | -700.38 | 0.1023 | -- | -100.00 | -- | -385.97 | -- | -25.76 | -- |
| Scandinavian ChemoTech AB | 5.03m | -15.70m | 38.18m | 5.00 | -- | 4.58 | -- | 7.59 | -0.8655 | -0.8655 | 0.2647 | 0.384 | 0.3162 | 0.5947 | 1.37 | 838,666.70 | -98.64 | -87.29 | -98.64 | -118.55 | 29.67 | 252.05 | -311.96 | -2,122.77 | -- | -22.93 | 0.00 | -- | 496.62 | 19.13 | 7.28 | -- | -- | -- |
| PMD Device Solutions AB | 51.91m | -43.42m | 44.45m | 37.00 | 0.3239 | -- | -- | 0.8563 | 5.06 | 5.06 | 3.54 | -5.52 | 0.8624 | -- | 4.47 | -- | -72.13 | -- | -- | -- | 82.86 | -- | -83.64 | -- | 0.1121 | -1.88 | -- | -- | -- | -- | -- | -- | -- | -- |
| iZafe Group AB | 6.29m | -31.99m | 58.30m | 7.00 | -- | 3.74 | -- | 9.27 | -0.1319 | -0.1319 | 0.0259 | 0.0567 | 0.1602 | 3.25 | 12.26 | 898,285.70 | -81.49 | -52.17 | -100.43 | -69.40 | -116.33 | -198.20 | -508.73 | -487.50 | 0.4406 | -43.46 | 0.3159 | -- | 149.93 | -24.79 | -36.76 | -- | -41.66 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 48.00 | 0.00% |
